Ocuphire Pharma, Inc.

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

Read Press Release

Restoring Vision and Clarity

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders.

SEE WHO WE ARE

CORPORATE PRESENTATION

A Clear-sighted Product Pipeline

APX3330

Targets: Diabetic Retinopathy and Diabetic Macular Edema

APX3330 is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammatory pathways relevant to retinal and choroidal vascular diseases.

View APX3330

Phentolamine Ophthalmic Solution 0.75%

Targets: Pharmacologically-induced Mydriasis, Presbyopia, and Dim Light or Night Vision Disturbances

Phentolamine Ophthalmic Solution 0.75% Eye Drops is a once-daily preservative-free eye drop formulation designed to reduce pupil size and improve visual acuity.

View Phentolamine Ophthalmic Solution 0.75%

Latest News

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences

View Release

Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September

View Release

Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium

View Release

Stock Snapshot

View Investor Relations